



IMDRF International Medical
Device Regulators Forum

IMDRF Stakeholders Forum

Regulatory Updates
ANVISA

14 September 2021
South Korea

Leandro Rodrigues Pereira
General Manager – Medical Devices Office
Brazilian Health Regulatory Agency
ANVISA



Construction of the Regulatory Agenda for 2021/2023



ANVISA
Regulatory Agenda

Publication of the Regulatory Agenda 2021 – 2023

➤ May 2021

Medical Devices

➤ 21 Regulatory projects

https://www.gov.br/anvisa/pt-br/assuntos/regulamentacao/agenda-regulatoria/agenda-2021-2023/arquivos/porta_lista_final_ar_2021-2023.pdf





Software as Medical Device Regulation

Public Consultation No. 1035/2021

Deadline for contributions ended on 06/15/21

Expected approval of the final document: End of 2021



Based on IMDRF documents:

- Software as a Medical Device (SaMD): Key Definitions (IMDRF/SaMD WG/N10FINAL:2013) (IMDRF, 2013)
- Software as a Medical Device (SaMD): Possible Framework for Risk Categorization and Corresponding Considerations (IMDRF/SaMD WG/N12FINAL:2014) (IMDRF, 2014)
- Software as a Medical Device (SaMD): Application of Quality Management System (IMDRF/SaMD WG/N23 FINAL:2015) (IMDRF, 2015)
- Software as a Medical Device (SaMD): Clinical Evaluation (SaMD WG (PD1)/N41R3) (IMDRF, 2017)
- Principles and Practices for Medical Device Cybersecurity (IMDRF/CYBER WG/N60FINAL:2020)



GMP Certification Requirements

Public Consultation No. 1041/2021

Deadline for contributions ended on 06/15/21

Expected approval of the final document: End of 2021



Main objectives:

- The purpose is to clarify some points of the standard under revision (RDC 183/2017) and simplify the submission process, reducing the number of documents required.
- Allows the use of international data from the IMDRF countries to support Certification.



Unique Device Identification (UDI)

Public Consultation No. 1051/2021

Deadline for contributions ended on 06/09/21

Key points:

Aligned with IMDRF documents

Phased implementation, starting with high-risk medical devices

- 2 years for risk class IV medical devices;
- 3 years for risk class III medical devices;
- 4 years for risk class II medical devices;
- 6 years for risk class I medical devices.





THANK YOU!

Leandro Rodrigues Pereira

General Manager
Medical Devices Office
Brazilian Health Regulatory Agency
ANVISA



ANVISA
Agência Nacional de Vigilância Sanitária

MINISTÉRIO DA
SAÚDE

